Capsid Titer

For Adeno-Associated Virus (AAV) gene therapy products, Capsid Titer is the quantitative measurement of the total number of viral capsid particles in a given volume, including both "full" capsids containing the therapeutic DNA genome and "empty" capsids that lack the genome. As a Critical Quality Attribute (CQA), the capsid titer is a fundamental measure of Quantity. It is essential for ensuring batch-to-batch manufacturing consistency and serves as the denominator for calculating the Full/Empty Capsid Ratio, a key purity attribute. Controlling the total capsid load administered to a patient is also a critical safety consideration due to the potential for immune responses to the capsid proteins.

• Reference Standard: There is no universal, public reference standard for capsid titer. Each developer must produce, meticulously characterize, and maintain their own in-house reference standard, which is critical for the accuracy and consistency of the assay over the product's lifecycle.
• Antibody Specificity & Quality: The antibodies used in the ELISA must be highly specific to conformational epitopes on the assembled capsid and must not recognize free or denatured capsid proteins. The quality and consistency of these critical reagents are paramount.
• Assay Variability: As a ligand-binding assay, the ELISA has inherent variability. This requires a robust, well-validated method and careful control over laboratory operations to ensure reliable results.

• Early Development: A qualified ELISA, often using a commercially available kit and a preliminary in-house reference material, is used to monitor process consistency.
• Mid-Development: The ELISA method is further optimized for the product's specific formulation and undergoes formal validation. The in-house reference standard is more thoroughly characterized.
• Late-Stage / BLA Submission: A fully validated, robust, and product-specific ELISA is required. The in-house reference standard must be extensively characterized with supporting stability data. The specification for capsid titer is set and justified based on manufacturing capability and clinical experience.
• By BLA submission, sponsors are expected to demonstrate orthogonal confirmation of capsid particle counts (e.g., via AUC or EM), even if ELISA remains the release method.

• Patient Risk: Capsid titer helps define the total AAV particle and capsid-protein load administered to the patient. An inaccurate capsid titer can distort interpretation of product strength, empty/full assessment, capsid burden, and dose-normalized quality attributes. This may affect evaluation of immunogenicity risk, product consistency, and the relationship between genome-containing particles and total particles.
• Manufacturing Risk: Inconsistent capsid titer values may indicate variability in upstream production, capsid assembly, harvest, purification, concentration, or formulation. Shifts in capsid titer should be interpreted alongside genome titer, empty/full ratio, aggregation, potency, and impurity data to determine whether the process remains under control.

Capsid titer provides context for interpreting how much total capsid material is present relative to genome-containing particles, potency, impurity burden, and administered dose.

Capsid titer is closely related to genome titer, but the two measurements answer different questions. Genome titer estimates the number of vector genomes, whereas capsid titer estimates total assembled capsid particles. Comparing these values can support interpretation of empty/full profile, but formal empty/full assessment may also rely on direct or orthogonal methods such as analytical ultracentrifugation, capillary electrophoresis, electron microscopy, SEC-MALS, or charge-detection mass spectrometry.

Capsid titer should also be interpreted with aggregation, visible/sub-visible particles, potency, and residual impurity data. A change in total capsid concentration may reflect altered upstream production, capsid assembly, purification recovery, concentration, or formulation behavior rather than a single isolated quality issue.

Total capsid measurement is commonly used in AAV CMC control strategies because it helps define total particle concentration, supports interpretation of genome titer, and provides context for empty/full assessment, product consistency, and capsid-protein exposure.

In practice, many AAV programs use a validated or qualified capsid ELISA when an appropriate serotype-specific or capsid-specific reagent set is available. However, capsid titer strategy is product- and method-dependent. Orthogonal technologies such as analytical ultracentrifugation, SEC-MALS, charge-detection mass spectrometry, or electron microscopy may be used for characterization, comparability, or confirmation of particle measurements depending on the development phase and control strategy.

The key CMC expectation is not that every AAV product must use the same assay format, but that the sponsor can justify how total capsid content is measured, trended, and interpreted alongside genome titer, empty/full ratio, purity, potency, and safety-relevant capsid load.

• Purity (ICH Q6B): Regulators view the ratio of full to empty particles as a critical purity attribute. The Capsid Titer measurement is an essential prerequisite for determining this ratio, and therefore falls under the expectation to control for product-related impurities.
• Validation (ICH Q2): The ELISA method used must be validated for its intended purpose. Key parameters include accuracy, precision, specificity (for the correct serotype), and range.